Navigation Links
Artificial Pancreas can Prevent the Development of Hypoglycemia
Date:6/18/2010

LONDON, June 18, 2010 /PRNewswire/ -- An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes.(1) Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.(2) The latest issue of the journal Diabetic Hypoglycemia (http://www.hypodiab.com) reviews advances in artificial pancreas design and production in further detail.

Dr Roman Hovorka, a leading artificial pancreas researcher and author of the Lancet paper(1) discusses developments in the field of closed-loop insulin delivery and reviews system components and challenges to the introduction of this technology into clinical practice, including the need for superfast-acting insulin analogs, dual hormone approaches to accelerate insulin absorption, and optimization of the clinical infrastructure to support the use of closed-loop systems.

Professor Simon Heller's related editorial details how technological developments supporting diabetes self-management have so far failed to lead to major improvements in glycemic control or to consistently reduced rates of severe hypoglycemia. He explains that one reason may be the requirement for patients to estimate both basal and prandial insulin doses, which can be demanding for many patients and may lead to ineffective diabetes self-management. Professor Heller discusses how the introduction of closed-loop systems might address this issue.

References

(1) Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. The Lancet 2010:375(9716):743-51.

(2) El-Khatib FH, Russell SJ, Nathan DM, et al. A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes. Sci Transl Med 2010:2(27):27ra27, published online 14 April 2010.

About Diabetic Hypoglycemia

Published by ESP Bioscience (Sandhurst, UK), Diabetic Hypoglycemia is an influential online diabetes journal led by Editor-in-Chief Professor Brian Frier (Edinburgh, UK), with Associate Editors: Professor Simon Heller (Sheffield, UK), Professor Christopher Ryan (Pittsburgh, USA) and Dr Rory McCrimmon (Dundee, UK). Published three times annually, Diabetic Hypoglycemia provides an interactive forum for the sharing of practical knowledge and opinions in the field of hypoglycemia.

To explore Diabetic Hypoglycemia, please take the guided tour: http://www.hypodiab.com/Teaser/hypodiab.html.

Diabetic Hypoglycemia is published by ESP Bioscience, supported by an unrestricted educational grant from Novo Nordisk A/S (Bagsvaerd, Denmark).

    Contact:

    Editorial Office
    E: enquiries@hypodiab.com
    T: +44(0)1344-762531
    F: +44(0)203-0514753



'/>"/>
SOURCE ESP Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scientists create artificial mini black hole
2. Cleveland researchers use natural and artificial sheaths to mend traumatic bone loss
3. First step to converting solar energy using artificial leaf
4. Scientists moving closer to artificial noses
5. Assembling cells into artificial 3-D microtissues, including a tiny gland
6. Scientists restore movement to paralyzed limbs through artificial brain-muscle connections
7. "Put Down the BBQ Ribs, We've Found You a Donor Heart," Nurse Tells Patient : Ohio Father near Death Gets Second Chance at Life with CardioWest™ temporary Total Artificial Heart
8. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
9. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
10. Stretchable silicon camera next step to artificial retina
11. Memory in artificial atoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):